MedTrace Logo

Gene Regulation by Thiazolidinediones

NCT00567593 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-08-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon

Conditions

Interventions

DRUG

Rosiglitazone

8mg tablet once a day for 14 days

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • James Lewis

    lead OTHER

Principal Investigators

  • James D Lewis, MD, MSCE · University of Pennsylvania

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567593 on ClinicalTrials.gov